Pen Needles Market

The pen needles market is projected to grow from USD 2.16 billion in 2026 to USD 3.37 billion by 2031, at a CAGR of 9.3% during the forecast period. As the global population increases, the demand for insulin administration devices, particularly pen needles, has shown substantial growth potential. Diabetes is a chronic condition characterized by high blood sugar, which has affected millions of people all over the world and often requires Type 1 and insulin-dependent Type 2 diabetes patients to take insulin regularly to maintain their blood glucose levels at normal values. The International Diabetes Federation estimates that the world's diabetic population could reach 783 million by 2045, intensifying the need for an efficient insulin delivery solution. Pen needles are a crucial part of an insulin pen, allowing patients to infuse insulin accurately, with less pain, and, above all, more conveniently than a syringe. Many companies are focusing on developing easy-to-handle, patient-friendly needle designs. These include thinner gauges and shorter lengths, which enhance patient convenience and compliance. Additionally, the availability of prefilled and disposable insulin pens, accompanied by pen needles, significantly simplifies diabetes management for elderly individuals, those with arthritis, or anyone with limited dexterity. Furthermore, advancements in technology, such as safety-engineered pen needles, help reduce concerns about needlestick injuries and improve compliance in healthcare settings. In this report, the pen needles market has been segmented on the basis of type, length, application, mode of purchase, setting, and region.

Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), MTD (Italy), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US).

To know about the assumptions considered for the study download the pdf brochure

Embecta Corp. (US)

One of Embecta's main products traded in the global market is pen needles. The company operates a US-based facility and production plants in Ireland and China. The company's vast range of pen needles, syringes, and safety injection devices is a fundamental factor that helps it withstand competition in the global market. Alongside standard pen needles, the company has a safety pen needle portfolio. The company approaches growth through both inorganic and organic mechanisms to cement its position in the pen needles market. In 2025, Embecta disclosed agreements with pharmaceutical partners to co-package its pen needles with potential generic GLP-1 therapies, positioning the company to benefit from the growing market for injectable diabetes and obesity treatments. The company also launched smaller pen needle pack sizes targeted at GLP-1 users and continues to pursue distribution and commercial partnership opportunities to expand market reach.

novo nordisk a/s (denmark)

The company's Diabetes and Obesity Care segment is its primary revenue source. The global diabetes market offers an opportunity for the firm to generate revenue through its Diabetes Care segment. The company reported approximately 40 million diabetic patients in 2022, up from 32 million in 2020. Novo Nordisk is well positioned in production, with ~12 major production sites across five geographical regions and a growing product portfolio, including pen needles. The company's R&D centers are located in China, Denmark, India, the UK, and the US. Novo Nordisk increased R&D investments from 16.6% in 2024 to 16.8% in 2025. The company also announced plans to expand its presence in the pen needles market through a research hub in the greater Boston metro area, announced in March 2023. In 2024, Novo Nordisk acquired three Catalent fill-finish facilities and announced a USD 4.1 billion expansion of its U.S. manufacturing capacity to support growing demand for pen-delivered therapies such as Ozempic and Wegovy.

b. braun se (germany)

B. Braun SE is another major player in the pen needles market. In terms of product, the group has a comprehensive presence across geographic markets. It is also recognized for its branded products, notably Omnican Fine and Omnican Fine Plus injection pen needles. Innovations such as the three-facet grinding tip, silicone coating, and thin-wall technologies used in injection pen needles will help the firm build a strong brand presence across the overall markets. The company has a broad geographic footprint and subsidiaries in 64 countries. Therefore, it is not dependent on a single market, which sustains its leading position. The company intends to focus on new technology and digital transformation for healthcare medical devices.

Market Ranking

The pen needles market is highly competitive, with five main players collectively accounting for approximately 75–91% of the total market share. Embecta Corp. stands out through its specialized focus on diabetes care and its extensive portfolio of pen needles designed to improve injection comfort and insulin delivery. Novo Nordisk A/S maintains a strong position through its established diabetes treatment portfolio and needle innovations, including NovoFine Plus and NovoTwist, which emphasize patient comfort, ease of use, and compatibility with injection pens. B. Braun SE strengthens its presence through its Omnican fine pen needles and broader expertise in medical devices and injection systems. Medical Technology and Devices S.p.A. contributes to the competitive landscape through its pen needle manufacturing and drug delivery device capabilities, while Terumo Corporation leverages its expertise in needle technology, precision manufacturing, and medical devices. The remaining 9–25% of the market is shared among other manufacturers, including Nipro Corporation, HTL-STREFA, UltiMed Inc., Allison Medical Inc., Artsana S.p.A., ARKRAY Inc., GlucoRx Limited, and Berpu Medical Technology, among others, contributing to market fragmentation and providing opportunities for smaller players to expand their presence. Market competition is driven by innovations in needle design, increasing demand for comfortable and safe injection devices, rising diabetes prevalence, and the expanding use of injectable therapies. Manufacturers are enhancing their product portfolios to improve patient experience, injection safety, and compatibility with drug delivery devices

Related Reports:

Pen Needles Market by Type (Standard Pen Needles, Safety Pen Neddles),Length (8mm, 5mm), Setting( Home Care Settings), Application (Glucagon like Peptide -1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase)- Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]